A weekly treatment for type 2 diabetes has proved safe and effective for patients in a trial involving 259 volunteers.
The formulation is a version of a previously available treatment called exenatide, which mimics one of the body's hormones. The existing version must be self-injected by patients twice daily. The trial showed that the slow-acting form was more effective than the original at keeping glucose levels in the blood under control, and more convenient to use.
"There is currently no available therapy for type 2 diabetes that patients can receive once a week," said Dr Daniel Drucker at the Samuel Lunenfeld Research Institute of Mount Sinai hospital in Toronto. The new formulation will need further clinical trials before being licensed for use by patients.